GSK

DID YOU KNOW ?

Accidental drug ingestion in children five years old and below, causes **50,000 VISITS** to the ER per year.[1] (US CDC data) *-CDC*

Accidental drug poisonings happen in **JUST ONE MINUTE** when parents turn their back on their child.[2]

CHILD-RESISTANT PACKAGING

According to the PPPA in the US, when applied and used appropriately, 'child-resistant' or 'special packaging' is a package that is significantly difficult for children under 5 to open but relatively easy for an adult to open.[a3-5]

CHILD-RESISTANT PACKAGING has been shown to prevent accidental drug poisonings.[6]

LAMICTAL CHILD-RESISTANT BLISTER[b]

3 simple steps to open Lamictal Child-resistant blister[7]

1



SEPARATE ONE TABLET

Tear along the cutting lines to separate one 'pocket' from the blister.

2

PEEL BACK THE OUTER LAYER

Starting at the corner, lift and peel over the pocket.

3

PUSH OUT THE TABLET

Gently push the tablet through the foil layer.

These images are for illustration purposes only and may not be an exact representation of the product.

Child-resistant packaging is the last line of defence in a series of protective measures. Parents or guardians are advised to keep medicinal products out of sight and out of reach from young children to ensure their safety.[5]

---

[a]A package is deemed to be child-resistant if at least 85% of children (42-51 months) are unable to access more than eight unit doses within the first five minutes and at least 80% of children are unable to access more than eight unit doses within ten minutes, while 90% of adults are able to access at least one unit dose in one minute.[5]

[b]Lamictal 25 mg, 50 mg, 100 mg and 200 mg chewable/dispersible tablets come in child-resistant packaging.[7]

The instructional video can be found by scanning the QR code:

References: 1. CDC. PROTECT Initiative: Advancing Children's Medication Safety. Last updated April 2020; **2.** Safe Medicine Storage: Recent Trends and Insights for Families and Health Educators. March 2018; **3.** United States Consumer Product Safety Commission. Business Guidance FAQ. Child Resistant and Senior Friendly Packaging (PPPA). https://www.cpsc.gov/Business-- Manufacturing/Business-Education/FAQ?p=3061&tid%5b3069%5d=3069. Accessed Jan 2023. **4.** Child Resistant Packaging. Consumer Healthcare Products Association https://www.chpa.org/public-policy-regulatory/regulation/regulation-otc-medicines/ child-resistant-packaging. Accessed Mar 2023. **5.** ISO 14375:2018 Child-resistant non-reclosable packaging for pharmaceutical products — Requirements and testing. https://www.iso.org/obp/ui/#iso:std:iso:14375:ed-1:v1:en. Accessed on Mar 2023. **6.** White *et al. American journal of lifestyle medicine.* 2018 Mar;12(2):117-9. **7.** Lamotrigine Global Datasheet, v50, January 2021

Abbreviations:
CDC: Centers for Disease Control and Prevention; **ER**: Emergency Room;
PPPA: Poison Prevention Packaging Act; **US**: United States

This leaflet is for educational purposes only. Consult your healthcare provider to seek further medical advice.

Lamictal (lamotrigine) 2mg, 5mg, 25mg, 50mg and 100mg dispersible/chewable tablets is a **prescription medicine** for the treatment of epilepsy in adults and children aged 2 years and older and in adults for the prevention of mood episodes in patients with bipolar. **Lamictal has risks and benefits** and should only be prescribed by a doctor experienced in treating epilepsy in adults and children aged 2 years and older or bipolar in adult patients. **Ask your doctor if Lamictal is right for you. Very common side effects:** skin rash, headache, somnolence, ataxia, and dizziness. This is not a full list. **If symptoms continue or you have side effects, see your doctor, pharmacist or healthcare professional. Use strictly as directed.** Lamictal is a funded medicine, normal doctor's charges apply. **For more information, including product details, see Lamictal consumer medicine information at www.medsafe.govt.nz.** Trademarks are owned by or licensed to the GSK group of companies. GlaxoSmithKline New Zealand Ltd. Auckland. **Adverse events involving GSK products should be reported to GSK Medical information on 0800 808 500.** Date of Approval: **07 2023** Date of expiry: **07 2025**

TAPS NP19557-PM-NZ-LMT-LBND-230001